Deucravacitinib

MILAN — Clinical efficacy was maintained with long-term use of deucravacitinib in plaque psoriasis, according to study results presented at the European Academy of Dermatology and Venereology Congress.

Bristol Myers Squibb’s deucravacitinib was approved by the FDA for the treatment of moderate to severe plaque psoriasis, the company announced in a press release.

Deucravacitinib was associated with improved efficacy and safety compared with both placebo and apremilast in a phase 3 cohort of adults with moderate to severe plaque psoriasis, according to a study.

Plaque psoriasis patients treated with deucravacitinib maintained improvement for up to 2 years, Bristol Myers Squibb announced in a press release.

Deucravacitinib, a TYK2 inhibitor, was well-tolerated and superior to placebo in improving ACR20 response among patients with psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.

The FDA has accepted a New Drug Application, while the European Medicines Agency validated a Marketing Authorization Application for deucravacitinib for the treatment of plaque psoriasis, Bristol Myers Squibb announced in a press release.